Cited by 552Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon MeasurementsMedical Imaging Techniques and Applications

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Open access
Sgouros, George, Roeske, John C., McDevitt, Michael R., Palm, Stig, Allen, Barry J., Fisher, Darrell R., Brill, A. Bertrand, Song, Hong +2 more·2010·Journal of Nuclear Medicine

Abstract

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.108.058651

Cites

363 of 363 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Beta- and gamma-radiation are viewed as having a relative biologic efficiency of 1.0, while emerging radiopharmaceutical therapies using alpha-particle emitters carry a much higher relative biologic efficiency.

    “Although b - and g -radiation are viewed as having a relative biologic ef fi ciency (RBE) of 1.0, other emerging RPTs, particularly those that use radionuclides that emit a -particles, carry much a higher RBE ( 21 ).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [59]Machinami R Ishikawa Y Boecker BB The international workshop on health effects of Thorotrast, radium, radon and other alpha-emitters, 1999 [preface] Radiat Res 1999 152 suppl S1 S2
  2. [68]Oliveira NG Castro M Rodrigues AS Wortmannin enhances the induction of micronuclei by low and high LET radiation [erratum] Mutagenesis 2003 18 217 12621080
  3. [100]Fisher DR The microdosimetry of monoclonal antibodies labeled with alpha emitters Schlafke-Stelson AT Watson EE Fourth International Radiopharmaceutical Dosimetry Symposium Oak Ridge, TN Oak Ridge Associated Universities 1986 26 36
  4. [103]Kellerer AM Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry Ebert HG Proceedings of the Second Symposium on Microdosimetry Brussels, Belgium Commission of European Communities 1970 107 134
  5. [153]Goodhead DT Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation Presented at: CERRIE Workshop July 21–23, 2003 Oxford, U.K.

Cited by

Sorted by citations

Authors
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G.
Affiliations
  • Johns Hopkins University (US)
  • Loyola University Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • International Atomic Energy Agency (AT)
  • Pacific Northwest National Laboratory (US)
  • Vanderbilt University (US)
  • Rutgers, The State University of New Jersey (US)
  • Texas A&M University (US)
Venue
Journal of Nuclear Medicine
Published
2010-01-15
Volume
51
Issue
2
Pages
311-328
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2018649196
Cited by
552
References
363
Citations by year
2026: 60 · 2025: 58 · 2024: 50 · 2023: 54 · 2022: 50 · 2021: 50 · 2020: 39 · 2019: 34 · 2018: 44 · 2017: 17 · 2016: 21 · 2015: 10 · 2014: 25 · 2013: 11 · 2012: 16
FWCI
9.79
Type
journal article
Language
en
Open access
Locations
  • Journal of Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (P50AG005136)
  • National Cancer Institute (R01CA109234, R41CA117599, P30CA008748)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB001994)
  • National Center for Research Resources (R43RR015155)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Health Professions › Radiological and Ultrasound Technology › Radioactivity and Radon Measurements
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
alpha-emitting radionuclides, targeted alpha therapy, radiation biology, dosimetry, radionuclide conjugation, radiopharmaceuticals, cancer therapy
MeSH terms
Alpha Particles, Cell Survival, Clinical Trials as Topic, Dose-Response Relationship, Radiation, Female, Humans, Male, Neoplasms, Neoplasms, Radiation-Induced, Pamphlets, Radiation-Protective Agents, Radiobiology, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Societies, Medical, Cell Death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review